PBMC Humanized Tumor Models for Evaluating T-cell Engagers
T-cell engagers (TCEs) are a class of bispecific antibody-based immunotherapies designed to bring T cells into close proximity with cancer...
Continue ReadingKnowledge Library
Evaluation of Bispecific Antibodies in NHPs
In recent years, bispecific antibodies (BsAbs) have emerged as a novel strategy in tumor immunotherapy. BsAbs combine two distinct antigen...
Continue Reading Custom Antibody and Protein Preparation Services
WuXi AppTec provides integrated and cost-effective services for: Polyclonal and monoclonal antibodies Anti-drug antibodies (ADA), host cell protein (HCP) antibodies,...
Continue Reading OncoWuXi Express: Review of SITC 2023 Annual Meeting
Review of SITC 2023 Annual Meeting The 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held...
Continue Reading
Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics
SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished...
Continue Reading
Combined Inhibition of KRAS G12C and PD1 Boosts Therapeutic Efficacy via Conditioning of Tumor Microenvironment
SITC Poster #466: Mutant KRAS is linked to PD-L1 expression, and oncogenic RAS signaling promotes an immunosuppressive tumor microenvironment by...
Continue Reading OncoWuXi Express: In vitro and in vivo evaluation of an mRNA-encoded bispecific antibody (EpCAM/CD3)
Introduction: Nucleic acid therapies can regulate the expression level or activity of disease-related targets at the genetic level, offering advantages...
Continue Reading WuXi AppTec in vitro Neuroscience Services
Neurological disorders, such as neurodegenerative diseases, epilepsy, chronic pain, psychiatric disorders, are one of today’s largest unmet medical needs. However,...
Continue Reading
